



ADLER & ASSOCIATES

P.O. BOX 710509
HOUSTON, TEXAS 77271-0509



WRITER'S DIRECT DIAL
(713) 270-5391
WRITER'S DIRECT FACS.
(713)-270-5361
E. MAIL: BADLER1@houston.rr.com

INTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)

February 25, 2004

Docket No.: D6401CIP

MS PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith for filing is the continuation-in-part patent application which claims benefit of priority under 35 U.S.C. 120 of U.S. Serial No. 10/143,293, filed May 10, 2002, which claims benefit of priority under 35 U.S.C. 119(e) of USSN 60/290,429, filed May 11, 2001, now abandoned in the:

Name of: **Aggarwal, et al.**

For: **Inhibitors of Receptor Activator Of NF- κ B And Uses Thereof**

CLAIMS AS FILED

<u>Fee for:</u>	<u>Small entity</u>	<u>Amount</u>
Basic fee	\$ 3 8 5	\$ 3 8 5
Each independent claim in excess of 3 (0)	\$ 4 3	\$ 0
Each claim excess of 20 (15)	\$ 9	\$ 1 3 5
Multiple dependent claim		
TOTAL FILING FEE		\$ 5 2 0

X Please charge my Deposit Account No. 07-1185 in the total amount of the filing fee and the assignment recordation fee if any.

X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1185.

X Any additional fees under 37 CFR 1.16.

X Any application processing fees under 37 CFR 1.17.

X Small Entity Statement

Applicants hereby claim small entity status under 37 CFR 1.27(a).

X Relate Back--35 U.S.C. 120

This continuation-in-part application claims benefit of priority under 35 U.S.C 120 of 10/143,293, filed May 10, 2002, which claims benefit of priority under 35 U.S.C. 119(e) of USSN 60/290,429, filed May 11, 2001, now abandoned.

X Sequence Listing

The sequence listing is enclosed, including a paper copy and a Request to Use Computer Readable Form from Another Application under 37 C.F.R. 1.821(e) requesting that the last filed computer readable form in Application Number 10/143,293, filed on May 10, 2002, be used as the computer readable form in the instant application.

X Drawings

Figures 1A-1B, 2A-2C, 3A-3B, 4A-4C, 5A-5C, 6A-6C, 7A-7F, 8, 9A-9C, and 10-12 are enclosed herewith on 18 sheets.

X Power of Attorney


X is attached.

X Address all future communications to:

Benjamin Aaron Adler
ADLER & ASSOCIATES
8011 Candle Lane
Houston TX 77071
(713) 270-5391
BADLER1@houston.rr.com

X Two photocopies of this sheet are enclosed.

Date: Feb 25, 2004


Benjamin Aaron Adler, Ph.D., J.D.
Registration No. 35,423
Counsel for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Aggarwal et al.	§	ART UNIT:
	§	
FILED: February 25, 2004	§	EXAMINER:
	§	
SERIAL NO.:	§	
	§	
FOR: Inhibitors of Receptor activator of	§	DOCKET:
NF-κB And Uses Thereof	§	D6401CIP

MS PATENT APPLICATION
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

Dear Sir:


I hereby certify that the following documents, which are attached, are being deposited, under 37 CFR 1.10, with the United States Postal Service "Express Mail Post Office to Addressee" service as Express Mail No. EV417704375US in an envelope addressed to: MS PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

- 1) Continuation-in-part application + 18 sheets of drawings;
- 2) Transmittal Letter;
- 3) Sequence Listing and Request to Use CRF;
- 4) Three (3) Combined Declarations and Powers of Attorney;
and
- 5) Return postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: Feb 25, 2004
 ADLER & ASSOCIATES
 8011 Candle Lane
 Houston, Texas 77071
 (713) 270-5391
 badler1@houston.rr.com


 Benjamin Aaron Adler, Ph.D., J.D.
 Registration No. 35,423
 Counsel for Applicant